Verastem (VSTM) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Program highlights and differentiation

• Lead program targets the RAF-MEK pathway with a clamp that blocks feedback reactivation and combines with a FAK inhibitor to address resistance, showing better results than single agents.

• FAK inhibitor offers a benign side effect profile and targets a universal resistance mechanism, validated in both preclinical and clinical studies.

• Combination regimens are now standard in pivotal studies, with expansion into lung and pancreatic cancer programs.

• FAK addition to regimens is gaining industry interest due to high response rates in early studies.

• Single-agent FAK showed limited activity, but combinations demonstrated significant efficacy, especially with avutometinib.

Clinical data and regulatory outlook

• Phase 2 data in low-grade serous ovarian cancer (LGSOC) showed a 22-month median PFS in KRAS mutant patients, outperforming standard chemotherapy.

• LGSOC is recognized as a distinct, chemo-resistant disease driven by MAPK mutations, with orphan drug status and unique patient needs.

• Other MEK inhibitors like trametinib have efficacy but are limited by toxicity, making long-term therapy challenging.

• KRAS mutation is a positive prognostic factor in LGSOC, with longer survival compared to wild-type; confirmatory studies are stratifying by KRAS status.

• Regulatory focus is on KRAS mutant population for initial approval, with confirmatory studies including wild-type; PFS is the primary endpoint.

Commercialization and market strategy

• Total addressable market for LGSOC therapies estimated above $3 billion, driven by long therapy duration and premium pricing.

• Market segmented by KRAS status and by incidence versus prevalence, with relapsed patients as key targets.

• Commercial strategy centers on educating healthcare providers and embedding guidelines in EMRs, focusing on 100 centers treating half the patients.

• Manufacturing capacity is sufficient for initial years, with backup suppliers in place.

• Inclusion in NCCN guidelines is critical for reimbursement and access, especially for Medicare patients.